CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK’s share price has fallen a lot in 10 months, which means it could be a huge bargain. I ran the key numbers and examined ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FTSE 100 index of leading shares has broken through 9,000 for the first time. That’s not as impressive as it ...

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Gilead is mounting a bid to tighten its grip on the HIV market. Having secured approval for twice-yearly HIV prevention product Yeztugo, the company has a shot at wresting more market share from GSK ...